Search Results

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Patients with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma MOA: Dostarlimab is a humanized anti-PD-1 IgG4 mAb. Key Eligibility Criteria: Unresected LA histologically confirmed HNSCC of the oral cavity,oropharynx (OPSCC), hypopharynx or larynx OPSCC p16 positive: T4…

Child and adult sitting together in front of a decorated Christmas tree. The holidays can be filled with celebrations and time spent with loved ones, but even in the best circumstances, it’s easy to feel overextended and anxious. Finding the balance between self-care and participation can put the focus on good health and cheer while…

We're sorry, your donation failed to process. Please try again or contact site support.